Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials

Ralph Corey, Gregory Moran, Richard V. Goering, Mekki Bensaci, Taylor Sandison, Carisa De Anda, Philippe Prokocimer

Research output: Contribution to journalArticle

Abstract

We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.

Original languageEnglish (US)
JournalDiagnostic Microbiology and Infectious Disease
DOIs
StatePublished - Jan 1 2019

Fingerprint

Linezolid
Phase III Clinical Trials
Skin
Infection
Methicillin-Resistant Staphylococcus aureus
Streptococcus
Staphylococcus
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections : pooled data from phase 3 clinical trials. / Corey, Ralph; Moran, Gregory; Goering, Richard V.; Bensaci, Mekki; Sandison, Taylor; De Anda, Carisa; Prokocimer, Philippe.

In: Diagnostic Microbiology and Infectious Disease, 01.01.2019.

Research output: Contribution to journalArticle

@article{10599ed3228b477e8bb32b0c06a58998,
title = "Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials",
abstract = "We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85{\%} for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.",
author = "Ralph Corey and Gregory Moran and Goering, {Richard V.} and Mekki Bensaci and Taylor Sandison and {De Anda}, Carisa and Philippe Prokocimer",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diagmicrobio.2019.01.017",
language = "English (US)",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections

T2 - pooled data from phase 3 clinical trials

AU - Corey, Ralph

AU - Moran, Gregory

AU - Goering, Richard V.

AU - Bensaci, Mekki

AU - Sandison, Taylor

AU - De Anda, Carisa

AU - Prokocimer, Philippe

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.

AB - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.

UR - http://www.scopus.com/inward/record.url?scp=85063566389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063566389&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.01.017

DO - 10.1016/j.diagmicrobio.2019.01.017

M3 - Article

C2 - 30940414

AN - SCOPUS:85063566389

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

ER -